Antimetastatic activity of a preventive cancer vaccine

Patrizia Nanni, Giordano Nicoletti, Arianna Palladini, Stefania Croci, Annalisa Murgo, Agnese Antognoli, Lorena Landuzzi, Marina Fabbi, Silvano Ferrini, Piero Musiani, Manuela Iezzi, Carla De Giovanni, Pier Luigi Lollini

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The development of prophylactic cancer vaccines that protect healthy hosts from tumor development leaves open the question whether such vaccines are also effective against established tumors and metastases. We tested the therapeutic activity of a proven prophylactic anti-HER-2/neu vaccine against successive stages of mammary carcinoma progression in HER-2/neu transgenic mice. The vaccine consisted of transgenic mammary carcinoma cells expressing HER-2/neu and two adjuvants: allogeneic class I histocompatibility antigens and interleukin (IL)-12. Vaccination of mice bearing lung micrometastases resulted in a 90% inhibition of metastasis development, whereas vaccination of mice with incipient local tumors was ineffective. The antimetastatic response was hampered by immune tolerance, as the protection of transgenic mice was lower than that of wild-type congenics not tolerant to HER-2/neu. A significant gain in immunotherapeutic activity in transgenic mice was obtained through the coadministration of anti-CD25 monoclonal antibody targeting regulatory T cells, which resulted in a >99% inhibition of metastasis. The immune responses elicited in transgenic mice comprised the activation of lung granulocytes and macrophages and of systemic adaptive responses based on helper T cells and their cytokines (IFN-γ and IL-4) and anti-HER-2/neu antibodies. Dissection of relevant antimetastatic mechanisms by means of knockout mice and of depleting antibodies revealed a major difference between tumor prevention, which was completely dependent on anti-HER-2/neu antibodies, and metastasis therapy, which was antibody independent. In conclusion, a vaccine successfully developed for cancer immunoprevention showed a strong therapeutic activity against lung metastases mediated by protective immune mechanisms distinct from those preventing the onset of primary mammary carcinoma.

Original languageEnglish
Pages (from-to)11037-11044
Number of pages8
JournalCancer Research
Volume67
Issue number22
DOIs
Publication statusPublished - Nov 15 2007

Fingerprint

Cancer Vaccines
Transgenic Mice
Neoplasm Metastasis
Vaccines
Antibodies
Neoplasms
Breast Neoplasms
Lung
Vaccination
Immune Tolerance
Neoplasm Micrometastasis
Histocompatibility Antigens Class I
Regulatory T-Lymphocytes
Interleukin-12
Helper-Inducer T-Lymphocytes
Granulocytes
Knockout Mice
Interleukin-4
Dissection
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nanni, P., Nicoletti, G., Palladini, A., Croci, S., Murgo, A., Antognoli, A., ... Lollini, P. L. (2007). Antimetastatic activity of a preventive cancer vaccine. Cancer Research, 67(22), 11037-11044. https://doi.org/10.1158/0008-5472.CAN-07-2499

Antimetastatic activity of a preventive cancer vaccine. / Nanni, Patrizia; Nicoletti, Giordano; Palladini, Arianna; Croci, Stefania; Murgo, Annalisa; Antognoli, Agnese; Landuzzi, Lorena; Fabbi, Marina; Ferrini, Silvano; Musiani, Piero; Iezzi, Manuela; De Giovanni, Carla; Lollini, Pier Luigi.

In: Cancer Research, Vol. 67, No. 22, 15.11.2007, p. 11037-11044.

Research output: Contribution to journalArticle

Nanni, P, Nicoletti, G, Palladini, A, Croci, S, Murgo, A, Antognoli, A, Landuzzi, L, Fabbi, M, Ferrini, S, Musiani, P, Iezzi, M, De Giovanni, C & Lollini, PL 2007, 'Antimetastatic activity of a preventive cancer vaccine', Cancer Research, vol. 67, no. 22, pp. 11037-11044. https://doi.org/10.1158/0008-5472.CAN-07-2499
Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A et al. Antimetastatic activity of a preventive cancer vaccine. Cancer Research. 2007 Nov 15;67(22):11037-11044. https://doi.org/10.1158/0008-5472.CAN-07-2499
Nanni, Patrizia ; Nicoletti, Giordano ; Palladini, Arianna ; Croci, Stefania ; Murgo, Annalisa ; Antognoli, Agnese ; Landuzzi, Lorena ; Fabbi, Marina ; Ferrini, Silvano ; Musiani, Piero ; Iezzi, Manuela ; De Giovanni, Carla ; Lollini, Pier Luigi. / Antimetastatic activity of a preventive cancer vaccine. In: Cancer Research. 2007 ; Vol. 67, No. 22. pp. 11037-11044.
@article{aa50ff19c31e4da49f169236644bccc7,
title = "Antimetastatic activity of a preventive cancer vaccine",
abstract = "The development of prophylactic cancer vaccines that protect healthy hosts from tumor development leaves open the question whether such vaccines are also effective against established tumors and metastases. We tested the therapeutic activity of a proven prophylactic anti-HER-2/neu vaccine against successive stages of mammary carcinoma progression in HER-2/neu transgenic mice. The vaccine consisted of transgenic mammary carcinoma cells expressing HER-2/neu and two adjuvants: allogeneic class I histocompatibility antigens and interleukin (IL)-12. Vaccination of mice bearing lung micrometastases resulted in a 90{\%} inhibition of metastasis development, whereas vaccination of mice with incipient local tumors was ineffective. The antimetastatic response was hampered by immune tolerance, as the protection of transgenic mice was lower than that of wild-type congenics not tolerant to HER-2/neu. A significant gain in immunotherapeutic activity in transgenic mice was obtained through the coadministration of anti-CD25 monoclonal antibody targeting regulatory T cells, which resulted in a >99{\%} inhibition of metastasis. The immune responses elicited in transgenic mice comprised the activation of lung granulocytes and macrophages and of systemic adaptive responses based on helper T cells and their cytokines (IFN-γ and IL-4) and anti-HER-2/neu antibodies. Dissection of relevant antimetastatic mechanisms by means of knockout mice and of depleting antibodies revealed a major difference between tumor prevention, which was completely dependent on anti-HER-2/neu antibodies, and metastasis therapy, which was antibody independent. In conclusion, a vaccine successfully developed for cancer immunoprevention showed a strong therapeutic activity against lung metastases mediated by protective immune mechanisms distinct from those preventing the onset of primary mammary carcinoma.",
author = "Patrizia Nanni and Giordano Nicoletti and Arianna Palladini and Stefania Croci and Annalisa Murgo and Agnese Antognoli and Lorena Landuzzi and Marina Fabbi and Silvano Ferrini and Piero Musiani and Manuela Iezzi and {De Giovanni}, Carla and Lollini, {Pier Luigi}",
year = "2007",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-07-2499",
language = "English",
volume = "67",
pages = "11037--11044",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Antimetastatic activity of a preventive cancer vaccine

AU - Nanni, Patrizia

AU - Nicoletti, Giordano

AU - Palladini, Arianna

AU - Croci, Stefania

AU - Murgo, Annalisa

AU - Antognoli, Agnese

AU - Landuzzi, Lorena

AU - Fabbi, Marina

AU - Ferrini, Silvano

AU - Musiani, Piero

AU - Iezzi, Manuela

AU - De Giovanni, Carla

AU - Lollini, Pier Luigi

PY - 2007/11/15

Y1 - 2007/11/15

N2 - The development of prophylactic cancer vaccines that protect healthy hosts from tumor development leaves open the question whether such vaccines are also effective against established tumors and metastases. We tested the therapeutic activity of a proven prophylactic anti-HER-2/neu vaccine against successive stages of mammary carcinoma progression in HER-2/neu transgenic mice. The vaccine consisted of transgenic mammary carcinoma cells expressing HER-2/neu and two adjuvants: allogeneic class I histocompatibility antigens and interleukin (IL)-12. Vaccination of mice bearing lung micrometastases resulted in a 90% inhibition of metastasis development, whereas vaccination of mice with incipient local tumors was ineffective. The antimetastatic response was hampered by immune tolerance, as the protection of transgenic mice was lower than that of wild-type congenics not tolerant to HER-2/neu. A significant gain in immunotherapeutic activity in transgenic mice was obtained through the coadministration of anti-CD25 monoclonal antibody targeting regulatory T cells, which resulted in a >99% inhibition of metastasis. The immune responses elicited in transgenic mice comprised the activation of lung granulocytes and macrophages and of systemic adaptive responses based on helper T cells and their cytokines (IFN-γ and IL-4) and anti-HER-2/neu antibodies. Dissection of relevant antimetastatic mechanisms by means of knockout mice and of depleting antibodies revealed a major difference between tumor prevention, which was completely dependent on anti-HER-2/neu antibodies, and metastasis therapy, which was antibody independent. In conclusion, a vaccine successfully developed for cancer immunoprevention showed a strong therapeutic activity against lung metastases mediated by protective immune mechanisms distinct from those preventing the onset of primary mammary carcinoma.

AB - The development of prophylactic cancer vaccines that protect healthy hosts from tumor development leaves open the question whether such vaccines are also effective against established tumors and metastases. We tested the therapeutic activity of a proven prophylactic anti-HER-2/neu vaccine against successive stages of mammary carcinoma progression in HER-2/neu transgenic mice. The vaccine consisted of transgenic mammary carcinoma cells expressing HER-2/neu and two adjuvants: allogeneic class I histocompatibility antigens and interleukin (IL)-12. Vaccination of mice bearing lung micrometastases resulted in a 90% inhibition of metastasis development, whereas vaccination of mice with incipient local tumors was ineffective. The antimetastatic response was hampered by immune tolerance, as the protection of transgenic mice was lower than that of wild-type congenics not tolerant to HER-2/neu. A significant gain in immunotherapeutic activity in transgenic mice was obtained through the coadministration of anti-CD25 monoclonal antibody targeting regulatory T cells, which resulted in a >99% inhibition of metastasis. The immune responses elicited in transgenic mice comprised the activation of lung granulocytes and macrophages and of systemic adaptive responses based on helper T cells and their cytokines (IFN-γ and IL-4) and anti-HER-2/neu antibodies. Dissection of relevant antimetastatic mechanisms by means of knockout mice and of depleting antibodies revealed a major difference between tumor prevention, which was completely dependent on anti-HER-2/neu antibodies, and metastasis therapy, which was antibody independent. In conclusion, a vaccine successfully developed for cancer immunoprevention showed a strong therapeutic activity against lung metastases mediated by protective immune mechanisms distinct from those preventing the onset of primary mammary carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=36348966738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348966738&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-2499

DO - 10.1158/0008-5472.CAN-07-2499

M3 - Article

C2 - 18006850

AN - SCOPUS:36348966738

VL - 67

SP - 11037

EP - 11044

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 22

ER -